International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group最新文献

{"title":"Eliminating cancer stem cells can inhibit progression of residual hepatocellular carcinoma after radiofrequency ablation.","authors":"Bing Wang, Yu-Han Shen, Song Wang, Zhong-Yi Zhang, Wei Wu, Kun Yan, Hao Wu, Wei Yang","doi":"10.1080/02656736.2026.2643510","DOIUrl":"10.1080/02656736.2026.2643510","url":null,"abstract":"<p><strong>Objectives: </strong>In this study, we aimed to examine the effects of cancer stem cells (CSCs) on residual hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA), and how to reduce the frequency of carcinoma cells with the CSCs phenotype in residual tumors after RFA.</p><p><strong>Materials & methods: </strong>Two HCC cell lines were exposed to 43 °C for 30 min <i>in vitro</i> using a water bath. Cell cycle, EdU assays and plate colony assays were performed to evaluate the proliferation of HCC cells. Cell migration was determined using wound healing and Transwell assays. Sphere formation and <i>in vivo</i> limiting dilution assays were performed to evaluate stemness. <i>In vivo</i>, two tumor-bearing mice were used to evaluate residual tumor growth, and treatments included an extracellular signal-regulated kinase (ERK) inhibitor U0126 and salinomycin (Sal).</p><p><strong>Results: </strong><i>In vitro</i>, sublethal heat accelerated cancer cell proliferation, migration, and stemness, and induced molecular changes of epithelial-mesenchymal transition (EMT), ERK, and the β-catenin pathway. ERK inhibitor and Sal inhibited the proliferation, migration, and stemness of heat-treated HCC cells. The results showed that, <i>in vivo</i>, the ERK inhibitor + Sal significantly inhibited the growth of residual tumors after incomplete RFA. Compared with incomplete RFA alone, EMT markers, ERK, and the β-catenin pathway were also significantly inhibited after treatment with ERK inhibitor + Sal.</p><p><strong>Conclusions: </strong>Incomplete RFA can accelerate cell proliferation, migration, and stemness in residual tumors. ERK inhibitor combined with Sal could inhibit cancer cell proliferation, migration, and stemness to synergically inhibit the progression of residual tumor.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2643510"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperthermia sensitizes cervical cancer to chemoradiotherapy by downregulating c-Myc/WSB1/β-catenin expression.","authors":"Lu Bai, Feng Li, Shasha Liu, Fangyu Shi, Penghua Cui, Jiyuan Yang, Qingshan Li, Ming Liu","doi":"10.1080/02656736.2026.2713197","DOIUrl":"https://doi.org/10.1080/02656736.2026.2713197","url":null,"abstract":"<p><strong>Background: </strong>WD repeat and SOCS box containing protein 1 (WSB1) promotes tumor progression and metastasis; however, its role in the response to hyperthermia combined with chemoradiotherapy in cervical cancer remains unclear. Therefore, this study investigated the involvement of WSB1 and the c-Myc/Wnt/β-catenin axis in the antitumor effects of this combined treatment.</p><p><strong>Methods: </strong><i>WSB1</i> expression was examined in multiple cervical cancer cell lines, and its functional roles were evaluated using the cell counting kit-8, colony formation, wound healing, Transwell migration/invasion, and apoptosis assays. The c-Myc-mediated transcriptional regulation of <i>WSB1</i> was analyzed using chromatin immunoprecipitation and dual-luciferase reporter assays. Wnt/β-catenin signaling activity and DNA damage were assessed via western blotting and immunofluorescence. Antitumor efficacy was further evaluated in a cervical cancer xenograft model treated with hyperthermia, chemoradiotherapy, or both.</p><p><strong>Results: </strong>WSB1 was highly expressed in both HeLa and SiHa cells and promoted proliferation, migration, and invasion, while inhibiting apoptosis. c-Myc directly transcriptionally activated <i>WSB1</i>, and WSB1 was required for c-Myc-driven activation of Wnt/β-catenin signaling, thereby forming a positive feedback loop. Combined hyperthermia and chemoradiotherapy markedly suppressed malignant phenotypes <i>in vitro</i> and tumor growth <i>in vivo</i>, increased DNA damage, and downregulated c-Myc, WSB1, and Wnt/β-catenin pathway components, with minimal systemic toxicity.</p><p><strong>Conclusions: </strong>WSB1 acts as an oncogenic driver in cervical cancer by sustaining c-Myc/Wnt/β-catenin signaling across different histological subtypes. Axis disruption via combined hyperthermia and chemoradiotherapy effectively inhibits tumor progression. This presents WSB1 and its signaling network as potential therapeutic targets for a broad range of patients with cervical cancer.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2713197"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148901835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a mobile high-intensity focused ultrasound platform for preclinical tumor microenvironment modulation in a pancreatic ductal adenocarcinoma mouse model.","authors":"Hye Won Shon, Seok-Ki Kim, Gyeongmin Kang, Mi Rim Lee, Yu-Sun Lee, Sumin Kang, Sun Il Choi, Jiyoung Lee, Daehong Kim, Yun-Hee Kim","doi":"10.1080/02656736.2026.2716349","DOIUrl":"https://doi.org/10.1080/02656736.2026.2716349","url":null,"abstract":"<p><strong>Purpose: </strong>High-intensity focused ultrasound (HIFU) is a noninvasive ablation technology with increasing relevance for preclinical research and clinical translation. Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with limited therapeutic options and poor response to current treatments, underscoring the urgent need for alternative strategies. To address this, we developed a mobile HIFU platform optimized for small-animal studies with an immersion-free design that improves usability while maintaining reproducible thermal ablation.</p><p><strong>Materials and methods: </strong>The system was evaluated in a PDAC mouse model using KPC tumor cells. HIFU-induced tumor ablation and tumor growth were assessed, and histological and flow cytometric analyses were performed to evaluate treatment-assossiacted changes in the tumor microenvironment. To recapitulate the PDAC immune microenvironment <i>in vitro</i>, we further established a co-culture system of tumor organoids and CD8+ T cells.</p><p><strong>Results: </strong>HIFU treatment induced tumor necrosis and significantly suppressed tumor growth. Histological and flow cytometric analyses revealed treatment-associated immune modulation, including increased proportions of activated CD8+ T cells, APC-like cells, and macrophage populations. In the organoid coculture model, activated CD8+ T cells accumulated around tumor organoids and were associated with increased tumor organoid death.</p><p><strong>Conclusions: </strong>The proposed mobile HIFU system demonstrated reliable technical performance and biological efficacy in a preclinical PDAC model. This platform offers a practical tool for reproducible small-animal HIFU studies and highlights the potential of ultrasound-based tumor ablation as a strategy to address unmet therapeutic needs in pancreatic cancer.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2716349"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148804510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the role of thermal ablation in thyroid cancer beyond low-risk unifocal PTMC: a review of the current state and future perspectives.","authors":"Yuhan Xie, Jianchuan Yang, Daoming Wu, Lingpeng Tang, Xiaoying Lin, Ting Hu, Songsong Wu","doi":"10.1080/02656736.2026.2627291","DOIUrl":"10.1080/02656736.2026.2627291","url":null,"abstract":"<p><strong>Background: </strong>Thermal ablation (TA) is an established treatment for low-risk unifocal papillary thyroid microcarcinoma (PTMC) and has been incorporated into several clinical guidelines. However, its clinical indications remain limited and do not fully encompass more advanced tumor stages, multifocal disease, or non-papillary histological subtypes. This review summarizes current evidence regarding the expanded application of TA in thyroid cancers beyond low-risk unifocal PTMC.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed, Embase, and Web of Science from database inception to May 2025. Eligible studies evaluating ultrasound-guided thermal ablation for papillary thyroid carcinoma beyond low-risk PTMC were identified according to predefined inclusion and exclusion criteria. Titles and abstracts were screened, followed by full-text assessment of potentially relevant articles. Relevant data were subsequently extracted for qualitative synthesis.</p><p><strong>Results: </strong>A total of 24 studies involving 1,940 patients with thyroid cancer beyond low-risk unifocal PTMC were included. The available evidence indicates that TA is technically feasible and minimally invasive in selected extended indications, achieving favorable short- to mid-term tumor control. In comparative studies, TA was generally associated with lower complication rates than surgery in appropriately selected patients. However, most included studies were retrospective in design, and long-term oncologic outcomes remain insufficiently reported, particularly for higher-risk pathological subtypes.</p><p><strong>Conclusions: </strong>TA may represent a minimally invasive therapeutic option for selected thyroid cancers beyond low-risk unifocal PTMC. Nevertheless, prospective studies with extended follow-up and direct comparative analyses with surgical management are required to better define its long-term oncologic role.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2627291"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147329074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing patient selection for thyroid thermal ablation: insights from a multidisciplinary team approach.","authors":"Sylvie Daclin, Gilles Russ, Sylvain Poiree, Jean Guillaume Marchand, Cécile Ghander, Malanie Roy, Fabrice Menegaux, Sebastien Gaujoux, Nathalie Chereau, Gabrielle Deniziaut, Claude Bigorgne, Camille Buffet, Adrien Ben Hamou","doi":"10.1080/02656736.2026.2634738","DOIUrl":"10.1080/02656736.2026.2634738","url":null,"abstract":"<p><strong>Introduction: </strong>Thermal ablation (TA) is increasingly used to treat benign thyroid nodules; however, a residual risk of occult malignancy persists despite two benign cytology results. We aimed to: (1) evaluate the proportion of non-benign histological results among patients excluded from TA during multidisciplinary team meetings (MDTMs); (2) identify clinical and ultrasonographic features suggestive of malignancy and (3) assess non-benign outcomes among patients treated with TA who subsequently underwent surgery.</p><p><strong>Methods: </strong>We conducted a retrospective single-center cohort study in a tertiary referral hospital between January 2019 and December 2023. Patients referred for TA with two benign cytology results but excluded after MDTM review were analyzed. Patients treated with TA who later underwent surgery were also reviewed. The primary endpoint was the proportion of non-benign histological results among surgically treated patients excluded from TA after MDTM review.</p><p><strong>Results: </strong>Among 573 patients discussed at MDTM, 131 (23%) were deemed ineligible for TA. Of these, 61 (47%) underwent surgery. Non-benign histology was identified in 6 of 61 operated patients (10%), corresponding to 4.6% of all excluded patients. Among 219 patients treated with TA, three (1.4%) required surgery during follow-up. Histology revealed one benign lesion, one noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), and one tumor of uncertain malignant potential.</p><p><strong>Conclusion: </strong>Systematic MDTM evaluation in an expert center identified non-benign nodules among patients excluded from TA, while non-benign outcomes after TA were rare. These findings should be interpreted cautiously given the retrospective design and limited number of events.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2634738"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of high-intensity focused ultrasound in gynaecological diseases.","authors":"Lei Li, Guorui Zhang, Mengyuan Sun, Jinghe Lang, Xin Yu","doi":"10.1080/02656736.2026.2635294","DOIUrl":"10.1080/02656736.2026.2635294","url":null,"abstract":"<p><strong>Background: </strong>High-intensity focused ultrasound (HIFU), a noninvasive treatment method, has attracted increasing attention in recent years for the management of gynaecological diseases. This review summarizes current literature on the application of HIFU in gynaecological diseases and discusses the advantages of HIFU compared with traditional surgery and other treatment strategies.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed, Embase and Web of Science from their inception to Dec 2025. Titles and abstracts were screened, and relevant data were extracted, followed by full-text quality assessment of the potentially relevant articles.</p><p><strong>Results: </strong>This studies have enrolled the application of HIFU in 135 studies in uterine fibroids, 42 studies in adenomyosis, 22 studies in caesarean scar pregnancy, 12 studies in endometriosis, 3 studies in cervicitis, 13 studies in vulvar diseases and 10 studies in placenta diseases. With accumulating clinical experience and ongoing technological advancements, HIFU has achieved improved efficacy and reduced rates of severe adverse events. In particular, HIFU may represent a well-tolerated option for patients seeking fertility preservation and does not appear to increase obstetric risk.</p><p><strong>Conclusion: </strong>HIFU is effective and recognized as a treatment for uterine fibroids, adenomyosis, and other benign gynaecological diseases. However, lack of high-quality long-term follow-up data remains. Patients can be more precisely selected and treated with appropriate therapy, minimizing adverse effects and decreasing the re-intervention rates. Noninvasive treatments such as HIFU are expected to become increasingly important in the next decade.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2635294"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147501605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of ultrasound ablation for uterine fibroids in patients with abdominal surgical scars on the acoustic pathway.","authors":"Junshu Li, Yong Wang, Chengqiu Qi, Changqing Pan, Jinyun Chen","doi":"10.1080/02656736.2026.2670494","DOIUrl":"10.1080/02656736.2026.2670494","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the safety and efficacy of ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation for uterine fibroids in patients with abdominal wall scars on the acoustic pathway.</p><p><strong>Methods: </strong>A total of 608 patients were included in the retrospective analysis. Preoperative and postoperative pelvic MRI data, treatment data, and follow-up information were collected. Patients were divided into scar group (213 cases: 172 transverse and 41 longitudinal abdominal wall scars) and non-scar group (395 cases). Treatment efficacy, adverse events, and complications were compared between groups.</p><p><strong>Results: </strong>The median fibroid ablation rates were similar in the scar and non-scar groups: 87.81% (IQR 78.20-98.80%) and 87.67% (IQR 75.18-96.75%), respectively (<i>p</i> = 0.403). The incidence of skin-burning sensation during operation in the scar group was significantly higher than that in the non-scar group [15.96% (34/213) vs 8.35% (33/395), <i>p</i> = 0.004]. Postoperative abdominal wall MRT2WI signal changes occurred in 22.37% (136/608) of cases, mainly in the subcutaneous fat layer (50%, 68/136), appearing as patchy mixed high signal on MRT2WI. These changes were higher in the scar group than in the non-scar group [28.17% (60/213) vs 19.24% (76/395), <i>p</i> = 0.012]. However, these abnormalities resolved spontaneously without intervention. No serious adverse events or complications occurred in either group during or after treatment.</p><p><strong>Conclusion: </strong>Abdominal wall surgical scars on the acoustic pathway do not significantly affect the safety and efficacy of USgHIFU for uterine fibroids.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2670494"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Verification and validation in canine cadaver of an MPI-integrable RF head coil for magnetic particle hyperthermia.","authors":"Hayden Carlton, Eli Mattingly, Abdul Rahman Mohtasebzadeh, Yash Sharad Lad, Shreeniket Pawar, Anilchandra Attaluri, Dara Kraitchman, Robert Ivkov, Patrick Goodwill","doi":"10.1080/02656736.2026.2672017","DOIUrl":"10.1080/02656736.2026.2672017","url":null,"abstract":"<p><strong>Purpose: </strong>Magnetic particle hyperthermia (MPH), the mild heating of solid tumors with magnetic nanoparticles, is an emerging treatment modality used as an adjuvant to therapies such as ionizing radiation. MPH can be paired with magnetic particle imaging (MPI) hardware to improve thermal treatment planning, spatially confined heating, and thermal dose delivery. In this work, we describe the design, verification, and validation of a radiofrequency (RF) head coil designed to integrate into a clinical MPI scanner.</p><p><strong>Methods: </strong>The RF coil was designed to accommodate an adult human head, provide a homogeneous (±10%) field along a 10 cm axial centerline, generate a peak magnetic flux density of 10 mT at 100 kHz, and be MPI compliant. Verification of the design consisted of a combination of magnetic field and nanoparticle heating measurements. To validate an MPI/MPH imaging and heating workflow, a canine cadaver was surgically prepared by implanting magnetic nanoparticles in the brain, followed by anatomical imaging, MPI, and heating with the head coil. To explore if the measured performance can be generalized to human treatment, we conducted a virtual MPH treatment of a human glioma.</p><p><strong>Results: </strong>Coil performance verification demonstrated RF fields as high as <math><mrow><msub><mrow><mi>B</mi></mrow><mrow><mtext>peak</mtext></mrow></msub><mo>=</mo><mn>14</mn></mrow></math> mT at 100.4 kHz, while achieving hyperthermic temperatures in tumor phantoms. The MPI scan of the canine cadaver head revealed differences in signal intensity between particle injection sites, which correlated with temperature increases measured during heating. Computational simulation of a human head showcased the feasibility of this system to treat gliomas.</p><p><strong>Conclusions: </strong>We successfully constructed, verified, and validated an MPI-compatible RF head coil for combined MPI/MPH therapy.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2672017"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13541239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, verification and validation of a spatially confined magnetic nanoparticle thermal therapy device for conformal thermal dose contouring.","authors":"Yash Sharad Lad, Shreeniket Pawar, Trent Townsend, Naveen Kondreddy, Anilchandra Attaluri","doi":"10.1080/02656736.2026.2717301","DOIUrl":"10.1080/02656736.2026.2717301","url":null,"abstract":"<p><strong>Background: </strong>Magnetic nanoparticle thermal therapy (MNTT) can localize heat within tumors, but non-uniform nanoparticle distribution can limit thermal dose coverage. Spatially confined MNTT (SC-MNTT) addresses this limitation by using a static magnetic field (SMF) to suppress heating outside a selected field-free region (FFR). However, SC-MNTT platforms require improved FFR steering and closed-loop temperature control.</p><p><strong>Purpose: </strong>This study developed and validated a low-cost, four-permanent-magnet SC-MNTT platform for spatially selective heating, dynamic FFR steering, and controlled thermal dose delivery in phantom models.</p><p><strong>Methods: </strong>The device combined four permanent magnets, an induction coil, motion and heating control, fiber-optic thermometry, and autotuning proportional-integral-derivative (PID) control. SMF maps and alternating magnetic field (AMF) defined operating conditions. Three-vial verification experiments evaluated spatially selective heating under pulsed AMF exposure. Liver-phantom validation experiments tested pulsed heating and autotuning PID control using prescribed temperature setpoint, a CEM43 target of 8 [min], and a healthy-tissue limit of 39.50 [°C].</p><p><strong>Results: </strong>The four-magnet configuration shifted the FFR between selected targets and concentrated heating at the intended nanoparticle location. In three-vial experiments, the selected vial reached normalized heating intensity near 1.00, while non-target vials remained lower between 0.09-0.26, corresponding to selective heating with reduced off-target activation. In liver-phantom experiments, autotuning PID control maintained a mean target temperatures 43.44 ± 0.01 [°C], achieved prescribed CEM43 at selected tumor probes, and kept the designated healthy-tissue probe below the safety threshold. Mean overshoot remained below 1.1 [%].</p><p><strong>Conclusion: </strong>The four-magnet SC-MNTT platform enabled repeatable in-plane FFR steering, spatially confined heating, and closed-loop thermal dose delivery in phantom models.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2717301"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148804452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statement of Retraction: Bipolar radiofrequency ablation with 2 × 2 electrodes as a building block for matrix radiofrequency ablation: <i>Ex vivo</i> liver experiments and finite element method modelling.","authors":"","doi":"10.1080/02656736.2026.2624217","DOIUrl":"https://doi.org/10.1080/02656736.2026.2624217","url":null,"abstract":"","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2624217"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}